New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTITCI, WCIC, INCY, TRVN, COV, RTEC, LJPC, HELI, GOLD, KLIC, EPE, NUTR, IVAC, APLOn The Fly: Analyst Initiation Summary
Atlas Pipeline Partners (APL) initiated with a Hold at Deutsche Bank... CHC Group (HELI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Overweight at JPMorgan... Intevac (IVAC) initiated with a Neutral at B. Riley... Kulicke & Soffa (KLIC) initiated with a Buy at B. Riley... La Jolla Pharmaceutical (LJPC) initiated with an Outperform at Wedbush... Nutraceutical (NUTR) initiated with an Outperform at Imperial Capital... Randgold Resources (GOLD) initiated with a Buy at UBS... Rudolph Technologies (RTEC) initiated with a Buy at B. Riley... Trevena (TRVN) initiated with an Outperform at JMP Securities... WCI Communities (WCIC) reinstated with an Outperform at Credit Suisse... Covidien (COV) initiated with a Buy at CRT Capital... Incyte (INCY) coverage assumed with a Buy at BofA/Merrill... Intra-Cellular (ITCI) initiated with an Outperform at Cowen.
News For APL;EPE;HELI;IVAC;KLIC;LJPC;NUTR;GOLD;RTEC;TRVN;WCIC;COV;INCY;ITCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
07:35 EDTIVACJefferies hosts a summit
Subscribe for More Information
August 24, 2015
07:02 EDTGOLDRandgold upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 19, 2015
10:30 EDTIVACIntevac management to meet with Benchmark
Subscribe for More Information
August 18, 2015
16:49 EDTLJPCOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.
08:06 EDTLJPCLa Jolla receives ophan drug designation for two compounds for FOP
Subscribe for More Information
08:03 EDTLJPCLa Jolla, Pharmaceutical, Vanderbilt enter research, license agreement
Subscribe for More Information
07:57 EDTITCIIntra-Cellular management to meet with Leerink
Subscribe for More Information
August 17, 2015
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use